Genpharmasec Reports Strong Q2 Results and Divestment of Clinigenome India
Genpharmasec Ltd · Financial Result · 03 Nov 2026, 11:02 pm
Genpharmasec Reports Strong Q2 Results and Divestment of Clinigenome India Genpharmasec reported consolidated revenue of ₹8,565.82 lakh for the quarter ended 30th Sep'26, up significantly from ₹3,263.71 lakh YoY and ₹4,971.03 lakh QoQ. Consolidated net profit swung to ₹102.92 lakh versus a net loss of ₹117.62 lakh in the prior-year period. In addition, the Board approved the complete divestment of wholly owned subsidiary Clinigenome India Private Limited to Micro Genomics India Private Limited by 31st Mar'27. Company Secretary Hardik Makwana tendered his resignation, effective 16th Nov'26.
Original exchange filing (PDF)
More announcements from Genpharmasec Ltd
- Statement of deviation or variation in the use of proceeds of Rights Issue for the Quarter ended 30th September, 2026. · 03 Nov 2026
- Outcome of the Meeting of Board of Directors held on Tuesday, 03rd November, 2026. · 03 Nov 2026
- Outcome of the Meeting of Board of Directors held on Tuesday, 03rd November, 2026. · 03 Nov 2026
- Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve 1. To consider and approve Un-audited .... · 03 Nov 2026
- Intimation under regulation 30 - Change of name of Subsidiary of the company. · 14 Oct 2026
- Disclosure of Voting Results and Scrutinizers report of the 34th Annual General Meeting held on 29th September, 2026. · 30 Sept 2026
- Submission of Proceeding of the 34th Annual General Meeting of the Member of the Genpharmasec Ltd held on Tuesday, 29th September, 2026. · 29 Sept 2026
- Annual Report for Financial Year 2025-26. · 07 Sept 2026
